Ads
related to: fasenra asthma medication dosage information sheet pdf- Administration Options
With FASENRA You May Have Options.
View At-Home & Self-Admin Info.
- Access FAQ
See Answers To Your Questions About
Your Condition & The FASENRA Pen.
- Patient Resources
Find Support Resources You May Need
When Starting FASENRA.
- See Approved Use
FASENRA May Help Treat Your
Condition, Find Out More.
- FASENRA 360
Sign Up For Personalized Resources
For Your FASENRA Journey.
- Considering FASENRA?
It May Be Time To Think Differently
About Your Treatment Options.
- Administration Options
Search results
Results From The WOW.Com Content Network
Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor . It was developed by MedImmune for the treatment of asthma. It is currently marketed by Astrazeneca. [3] [4] Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016.
Aspirin-exacerbated respiratory disease (AERD), also called NSAID-exacerbated respiratory disease (N-ERD) or historically aspirin-induced asthma and Samter's Triad, is a long-term disease defined by three simultaneous symptoms: asthma, chronic rhinosinusitis with nasal polyps, and intolerance of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs).
AstraZeneca's (AZN) asthma drug, Fasenra, maintains improvements achieved over first year of treatment in severe eosinophilic asthma patients for the next 56 weeks.
An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...
In studies, mepolizumab cut the necessity for hospitalisation due to asthma exacerbations in half, as compared to placebo. [ 9 ] In December 2017, the FDA expanded mepolizumab's indication to treat adults with eosinophilic granulomatosis with polyangiitis , which is a rare autoimmune condition that can cause vasculitis .
In the United States. it was approved by the Food and Drug Administration (FDA) under the trade name Arcapta Neohaler on July 1, 2011) [12] olodaterol: approved in some European countries and Russia, and by the U.S. Food and Drug Administration (FDA) on July 31, 2014, under Striverdi Respimat [13]
Ad
related to: fasenra asthma medication dosage information sheet pdf